Frontier Biotechnologies Past Earnings Performance
Past criteria checks 0/6
Frontier Biotechnologies's earnings have been declining at an average annual rate of -11.5%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 32.3% per year.
Key information
-11.5%
Earnings growth rate
-5.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 32.3% |
| Return on equity | -24.4% |
| Net Margin | -209.4% |
| Next Earnings Update | 25 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Frontier Biotechnologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 134 | -280 | 151 | 162 |
| 30 Jun 24 | 123 | -316 | 155 | 175 |
| 31 Mar 24 | 127 | -309 | 160 | 204 |
| 31 Dec 23 | 114 | -329 | 160 | 214 |
| 30 Sep 23 | 99 | -373 | 144 | 273 |
| 30 Jun 23 | 101 | -407 | 148 | 305 |
| 31 Mar 23 | 91 | -373 | 142 | 283 |
| 31 Dec 22 | 85 | -357 | 137 | 274 |
| 30 Sep 22 | 64 | -309 | 138 | 226 |
| 30 Jun 22 | 44 | -290 | 141 | 197 |
| 31 Mar 22 | 40 | -274 | 141 | 181 |
| 31 Dec 21 | 41 | -260 | 138 | 172 |
| 30 Sep 21 | 58 | -244 | 146 | 147 |
| 30 Jun 21 | 63 | -222 | 128 | 138 |
| 31 Mar 21 | 51 | -228 | 116 | 142 |
| 31 Dec 20 | 47 | -231 | 110 | 138 |
| 30 Sep 20 | 33 | -223 | 88 | 120 |
| 31 Dec 19 | 21 | -192 | 87 | 85 |
| 31 Dec 18 | 2 | -247 | 164 | 87 |
Quality Earnings: 688221 is currently unprofitable.
Growing Profit Margin: 688221 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688221 is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare 688221's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688221 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688221 has a negative Return on Equity (-24.36%), as it is currently unprofitable.